Efficacy of Everolimus with Reduced Cyclosporine in Japanese De Novo Renal Transplant Recipients: 24-Month, Randomized, Multicenter Study.

被引：0
|
作者：
Saito, K. [1 ]
Uchida, K. [2 ]
Takahara, S. [3 ]
Yoshimura, N. [4 ]
Teraoka, S. [5 ]
Cornu-Artis, C. [6 ]
Kobayashi, E. [7 ]
Takahashi, K. [1 ]
机构：
[1] Niigata Univ, Niigata, Japan
[2] Aichi Med Univ, Aichi, Japan
[3] Osaka Univ, Osaka, Japan
[4] Kyoto Prefectural Univ Med, Kyoto, Japan
[5] Int Univ Hlth & Welf, Atami Hosp, Shizuoka, Japan
[6] Novartis Pharma AG, Basel, Switzerland
[7] Jichi Med Univ, Shimotsuke, Tochigi, Japan
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2013年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：314 / 314
页数：1
相关论文
共 50 条
  • [41] Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month Study
    Holdaas, Hallvard
    Rostaing, Lionel
    Seron, Daniel
    Cole, Edward
    Chapman, Jeremy
    Fellstrom, Bengt
    Strom, Erik H.
    Jardine, Alan
    Midtvedt, Karsten
    Machein, Uwe
    Ulbricht, Bettina
    Karpov, Alexander
    O'Connell, Philip J.
    TRANSPLANTATION, 2011, 92 (04) : 410 - 418
  • [42] EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED TACROLIMUS AND EARLY STEROID ELIMINATION REGIMEN IN DE NOVO PEDIATRIC RENAL TRANSPLANT RECIPIENTS: 12-MONTH DATA FROM THE CRADLE STUDY.
    Toenshoff, B.
    Ettenger, R.
    Christian, M.
    Bjerre, A.
    Strologo, L. D.
    Marks, S. D.
    Pape, L.
    Martzloff, E-D.
    Rauer, B.
    Ng, J.
    Lopez, P. M.
    PEDIATRIC TRANSPLANTATION, 2017, 21 : 1 - 1
  • [43] Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials
    Lee, Sung-Gyu
    Jeng, Long-Bin
    Saliba, Faouzi
    Soin, Arvinder Singh
    Lee, Wei-Chen
    De Simone, Paolo
    Nevens, Frederik
    Suh, Kyung-Suk
    Fischer, Lutz
    Joo, Dong Jin
    Fung, John
    Joh, Jae-Won
    Kaido, Toshimi
    Grant, David
    Meier, Matthias
    Rauer, Barbara
    Sips, Carole
    Kaneko, Shuhei
    Levy, Gary
    TRANSPLANTATION, 2021, 105 (07) : 1564 - 1575
  • [44] THE TRANSFORM STUDY: 12-MONTH EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS
    Pascual, Julio
    Berger, Stefan
    Witzke, Oliver
    Chadban, Steve
    Oppenheimer, Federico
    Oberbauer, Rainer
    Watarai, Yoshihiko
    Legendre, Christophe
    Luo, Wen-Lin
    Marti, Anamaria
    Bernhardt, Peter
    Tedesco, Helio
    TRANSPLANT INTERNATIONAL, 2017, 30 : 159 - 159
  • [45] EFFECT OF TACROLIMUS EXPOSURE ON EVEROLIMUS-BASED IMMUNOSUPPRESSION IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: A 24-MONTH ANALYSIS FROM TRANSFORM STUDY
    Citterio, Franco
    Peddi, V. Ram
    Qazi, Yasir
    Kim, Dean
    Vincenti, Flavio
    Berger, Stefan
    Sommerer, Claudia
    Gawai, Apurva
    Hernandez-Gutierrez, Maria-Pilar
    Bernhardt, Peter
    Oberbauer, Rainer
    TRANSPLANT INTERNATIONAL, 2021, 34 : 254 - 255
  • [46] CYTOMEGALOVIRUS AND BK VIRUS INFECTIONS ARE LESS FREQUENT WITH EVEROLIMUS VERSUS MYCOPHENOLATE IMMUNOSUPPRESSION: 24-MONTH UPDATE FROM THE 2309 STUDY IN DE NOVO RENAL TRANSPLANT RECIPIENTS
    Yaqoob, M.
    Pattison, J.
    Riad, H.
    Cornu-Artis, C.
    Wang, Z.
    Shihab, F.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 40 - 41
  • [47] Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study.
    Chadban, S.
    Mulgaonkar, S.
    Pascual, J.
    Tedesco, H.
    Berger, S.
    Qazi, Y.
    Legendre, C.
    Basic-Jukic, N.
    Bernhardt, P.
    Vincenti, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 475 - 475
  • [48] ASSESSMENT OF PROTEINURIA REPORTED AS ADVERSE EVENTS IN DE NOVO RENAL TRANSPLANT RECIPIENTS RECEIVING AN EVEROLIMUS-BASED REGIMEN: 24-MONTH RESULTS FROM TRANSFORM
    Legendre, C.
    Buchler, M.
    Pernin, V.
    Berger, S. P.
    Oppenheimer, F.
    Wiseman, A.
    Viklicky, O.
    Russ, G. R.
    Danguilan, R.
    Basic-Jukic, N.
    Mor, E.
    Narvekar, P.
    Hernandez-Gutierrez, M. P.
    Bernhardt, P.
    Gharbi, H.
    Sommerer, C.
    TRANSPLANT INTERNATIONAL, 2020, 33 : 5 - 5
  • [49] Renal Function Outcomes by HLA Mismatch in De Novo Kidney Transplant Recipients Receiving Everolimus PlusReduced-Dose Cyclosporine versus Mycophenolate Plus Standard-Dose Cyclosporine: 24-Month Subanalysis of A1202 Study
    Yoshida, K.
    Watarai, Y.
    Nakagawa, K.
    Kamisawa, O.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 737 - 738
  • [50] Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial
    De Simone, P.
    Nevens, F.
    De Carlis, L.
    Metselaar, H. J.
    Beckebaum, S.
    Saliba, F.
    Jonas, S.
    Sudan, D.
    Fung, J.
    Fischer, L.
    Duvoux, C.
    Chavin, K. D.
    Koneru, B.
    Huang, M. A.
    Chapman, W. C.
    Foltys, D.
    Witte, S.
    Jiang, H.
    Hexham, J. M.
    Junge, G.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 (11) : 3008 - 3020
12345